Floatz logo

Clostridium Butyricum

Low Anterior Resection Syndrome

Sixth Affiliated Hospital, Sun Yat-sen Universityother_biologicalPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Low Anterior Resection Syndrome cohort.

Asset / SponsorPhaseRating
GLYCERIN,ANHYDROUS
University of Aarhus
Phase 3B
Capecitabine
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Phase 2/3B
Intra-Rectal Botulinum Toxin A
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2B
Enterococcus faecalis T-110
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2CCC
Bacillus mesentericus TO-A
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2CCC
Loperamide
Ohio State University Comprehensive Cancer Center
N/AD

Same molecule, other indications

Clostridium Butyricum is also rated in:

chemotherapy-induced toxicityDormant
B
Indicative ·
62 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
54 / 100
View asset →
malignant colon neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →